Centre for Integrative Clinical and Molecular Medicine, The University of Queensland, School of Medicine, Brisbane, Australia.
Complement Ther Med. 2013 Jun;21(3):164-71. doi: 10.1016/j.ctim.2012.12.006. Epub 2013 Jan 8.
The aim of the study was to determine if a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) combination was effective in reducing the number of colds and in turn improving symptom recovery in a cohort of males and females that reported frequently contracting a cold.
A double blind randomized placebo-controlled clinical trial.
One-hundred and twenty-six participants matched by age, BMI, dietary and physical parameters with self-reported frequent upper respiratory tract symptoms and infections were randomly assigned to receive 600 mg of Lf/IgF or a placebo daily for 90 days.
A total of 90 participants (47 receiving the active and 43 placebo) completed the 90 day trial and 15 completed 45 days participation (6 in the active and 9 in the placebo group). The total number of colds recorded over the study period was 48 for the treatment group versus 112 for the placebo group (p < 0.001). The significant trend was retained when the data was corrected for medications returned (p < 0.001) and for guessing treatment allocations (p < 0.001). Non-parametric analysis demonstrated that the total number of cold-associated symptoms reported by participants that received Lf/IgF was significantly less than those in the placebo group (p < 0.05). Also, total days sick with a cold and cold severity were reduced over the clinical trial period for Lf/IgF over placebo, but the trend was not significant.
These findings demonstrate that the Lf/IgF combination significantly decreased the incidence of colds and the cumulative number of cold-related symptoms over placebo. This therapeutic combination may be indicated for the prevention of colds and its most common symptoms in the general population when administered as a preventative supplement.
本研究旨在确定牛乳铁蛋白/乳清蛋白 Ig 丰富部分（Lf/IgF）的组合是否能有效减少感冒的次数，并改善经常感冒的男性和女性的症状恢复情况。
双盲、随机、安慰剂对照临床试验。
126 名参与者按年龄、BMI、饮食和身体参数与自我报告的上呼吸道症状和感染频繁匹配，随机分配每天接受 600 毫克 Lf/IgF 或安慰剂，共 90 天。
共有 90 名参与者（47 名接受活性治疗，43 名接受安慰剂）完成了 90 天的试验，15 名参与者完成了 45 天的参与（活性组 6 名，安慰剂组 9 名）。在研究期间，治疗组记录的感冒总数为 48 次，而安慰剂组为 112 次（p<0.001）。当对返回的药物进行校正（p<0.001）和猜测治疗分配（p<0.001）时，数据仍然存在显著趋势。非参数分析表明，接受 Lf/IgF 治疗的参与者报告的与感冒相关的症状总数明显少于安慰剂组（p<0.05）。此外，在临床试验期间，Lf/IgF 组的总感冒天数和感冒严重程度均低于安慰剂组，但趋势不显著。
这些发现表明，Lf/IgF 组合显著降低了感冒的发生率和与安慰剂相比的感冒相关症状的累积数量。当作为预防补充剂使用时，这种治疗组合可能对预防普通人群的感冒及其最常见症状有效。
